As India’s contract manufacturing and development organization (CDMO) is set to double in the next decade, Anthem Biosciences ...

Anthem Biosciences, an India-based CDMO, submitted a filing (PDF) at the end of 2024 to announce its plans for a 33.95 ...

(Reuters) -Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion ... are among investors who will sell shares in the IPO. The company will not sell any shares and it did not ...

India-based drug manufacturer Anthem Biosciences has its sights on going public with an IPO that could raise 34 billion rupees ($397 million).

Anthem Biosciences Limited, an innovation-driven and technology ... SEBI to raise funds through an initial public offering (IPO). Ajay Bhardwajm, chairman, MD & CEO, Ishaan Bhardwaj, vice president, ...

Anthem Biosciences on Tuesday (December 31 ... The proposed initial public offer (IPO) is entirely an offer for sale (OFS) worth ₹3,395 crore by promoters, investors and other selling ...

Indian contract drugmaker Anthem Biosciences filed for a ₹3,395 crore ... are among the investors who will sell shares in the IPO. The company will not sell shares and did not give any other ...

The Bengaluru-based pharma company is run by Ajay Bhardwaj, a former Biocon executive, who is the founder, CEO and Managing Director at Anthem Biosciences. The company was incorporated in 2006.

Dec 31 (Reuters) - Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion ... are among investors who will sell shares in the IPO. The company will not sell any shares and it ...

Contract research company Anthem Biosciences has filed for a Rs 3,395 ... The selling shareholders will be entitled to the proceeds from the IPO and the company will not receive any proceeds ...